+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Imfinzi"

From
Gemcitabine Hydrochloride Global Market Report 2025 - Product Thumbnail Image

Gemcitabine Hydrochloride Global Market Report 2025

  • Report
  • January 2025
  • 175 Pages
  • Global
From
From
From
From
Bladder Cancer Market Report and Forecast 2025-2034 - Product Thumbnail Image

Bladder Cancer Market Report and Forecast 2025-2034

  • Report
  • June 2025
  • 400 Pages
  • Global
From
From
From
IMFINZI Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

IMFINZI Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
Disease Analysis: Non-Small Cell Lung Cancer (NSCLC) - Product Thumbnail Image

Disease Analysis: Non-Small Cell Lung Cancer (NSCLC)

  • Report
  • April 2021
  • 191 Pages
  • Global
Market Spotlight: Small-Cell Lung Cancer (SCLC) - Product Thumbnail Image

Market Spotlight: Small-Cell Lung Cancer (SCLC)

  • Report
  • November 2020
  • 49 Pages
  • Global
From
  • 16 Results (Page 1 of 1)
Loading Indicator

Imfinzi (durvalumab) is a monoclonal antibody drug used to treat certain types of non-small cell lung cancer (NSCLC). It is used in combination with other drugs to treat patients with locally advanced or metastatic NSCLC who have not received prior treatment. Imfinzi works by blocking the action of a protein called PD-L1, which helps cancer cells to evade the body's immune system. Imfinzi is approved by the US Food and Drug Administration (FDA) for the treatment of NSCLC and is currently being studied in clinical trials for other types of cancer. The Imfinzi market is highly competitive, with several major pharmaceutical companies developing and marketing drugs for the treatment of NSCLC. These include AstraZeneca, Bristol-Myers Squibb, Merck, Pfizer, and Roche. Other companies, such as AbbVie, Amgen, and Novartis, are also developing drugs for the treatment of NSCLC. Show Less Read more